T-cell receptor gene therapy clinically targeting a TP53 public neoantigen Editorial
| Author: | Klebanoff, C. A. |
| Title: | T-cell receptor gene therapy clinically targeting a TP53 public neoantigen |
| Abstract: | T-cell receptors (TCR) are an antigen receptor class that can uniquely respond to epitopes resulting fromcytosolic and intranuclear proteins. In this issue, Kim and colleagues report the first successful application of TCR gene therapy targeting a shared, or public, neoantigen resulting from a TP53 hotspot mutation.These results establish clinical proof of concept that an off-the-shelf TCR targeting a recurrent mutation in a molecular driver of oncogenesis can benefit patients with metastatic cancer. © 2022 American Association for Cancer Research. |
| Keywords: | genetics; mutation; neoplasm; neoplasms; t lymphocyte; tumor associated leukocyte; lymphocytes, tumor-infiltrating; t-lymphocytes; metabolism; protein p53; tumor antigen; immunology; antigens, neoplasm; receptors, antigen, t-cell; tumor suppressor protein p53; tp53 protein, human; lymphocyte antigen receptor; t lymphocyte receptor gene; genes, t-cell receptor; humans; human |
| Journal Title: | Cancer Immunology Research |
| Volume: | 10 |
| Issue: | 8 |
| ISSN: | 2326-6066 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2022-08-01 |
| Start Page: | 919 |
| Language: | English |
| DOI: | 10.1158/2326-6066.Cir-22-0386 |
| PUBMED: | 35767244 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 September 2022 -- Source: Scopus |
